Journal of Autism and Developmental Disorders

, Volume 43, Issue 10, pp 2435–2441

Systematic Review and Meta-analysis of Pharmacological Treatment of the Symptoms of Attention-Deficit/Hyperactivity Disorder in Children with Pervasive Developmental Disorders

  • Brian Reichow
  • Fred R. Volkmar
  • Michael H. Bloch
Original Paper

Abstract

Many children with pervasive developmental disorders (PDD) exhibit behaviors and symptoms of attention-deficit/hyperactivity disorder (ADHD). We sought to determine the relative efficacy of medications for treating ADHD symptoms in children with PDD by identifying all double-blind, randomized, placebo-controlled trials examining the efficacy of medications for treating ADHD symptoms in children with PDD. We located seven trials involving 225 children. A random effects meta-analysis of four methylphenidate trials showed methylphenidate to be effective for treating ADHD symptoms in children with PDD (ES = .67). Several adverse events were greater for children were taking methylphenidate compared to placebo. An individual trial of clonidine and two trials of atomoxetine suggest these agents may also be effective in treating ADHD symptoms in children with PDD.

Keywords

Autism Pervasive developmental disorder Attention deficit/hyperactivity disorder Methylphenidate Meta-analysis Atomoxetine Clonidine ADHD ASD Autism spectrum disorder PDD PDD-NOS 

References

  1. Aman, M. G., Arnold, L., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., et al. (2005). Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology, 15(6), 869–884.PubMedCrossRefGoogle Scholar
  2. American Psychiatric Association. (2000). Diagnostic and statistical manual (4th ed., text revision). Washington, DC: American Psychiatric Association.Google Scholar
  3. Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., et al. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45(10), 1196–1205.PubMedCrossRefGoogle Scholar
  4. Borenstein, M., Hedges, L., Higgins, J., & Rothstein, H. (2005). Comprehensive meta-analysis 2. Englewood, NJ: Biostat.Google Scholar
  5. Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents—meta-analytsis and meta-regression analysis. Pyschopharmacology, 194(2), 197–209.CrossRefGoogle Scholar
  6. Conners, C. (2001). Conners’ rating scales-revised: Technical manual. North Tonawanda, NY: Multi-Health Systems.Google Scholar
  7. Connor, D., Fletcher, K. E., & Swanson, J. M. (1999). A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38(12), 1551–1559.PubMedCrossRefGoogle Scholar
  8. DuPaul, G. J., Anastopoulos, A. D., Power, T. J., Reid, R., Ikeda, M. J., & McGoey, K. E. (1998). Parent ratings of attention-deficit/hyperactivity disorder symptoms: factor structure and normative data. Journal of Psychopathologic Behavioral Assessment, 20, 83–102.CrossRefGoogle Scholar
  9. Faraone, S., & Buitelaar, J. (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European Child and Adolescent Psychiatry, 19, 353–364.PubMedCrossRefGoogle Scholar
  10. Frazier, J. A., Biederman, J., Bellordre, C. A., Garfield, S. B., Geller, D. A., Coffey, B. J., et al. (2001). Should the diagnosis of attention-deficit/hyperactivity disorder be considered in children with pervasive developmental disorder? Journal of Attention Disorder, 4(4), 203–211.CrossRefGoogle Scholar
  11. Gargaro, B. A., Rinehart, N. J., Bradshaw, J. L., Tonge, B. J., & Sheppard, D. M. (2011). Autism and ADHD: How far have we come in the comorbidity debate? Neuroscience and Biobehavioral Review, 35, 1081–1088.CrossRefGoogle Scholar
  12. Ghuman, J. K., Aman, M. G., Lecavalier, L., Riddle, M. A., Gelenberg, A., Wright, R., et al. (2009). Randomized, placebo-controlled, cross-over study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. Journal of Child and Adolescent Psychopharmacology, 19(4), 329–339.PubMedCrossRefGoogle Scholar
  13. Grzadzinski, R., Di Martino, A., Brady, E., Mairena, M. A., O'Neale, M., Petkova, E., et al. (2011). Examining autistic traits in children with ADHD: Does the autism spectrum extend to ADHD? Journal of Autism and Developmental Disorders, 41(9), 1178–1191.PubMedCrossRefGoogle Scholar
  14. Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.PubMedCrossRefGoogle Scholar
  15. Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., et al. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 51(7), 733–741.PubMedCrossRefGoogle Scholar
  16. Hazell, P. (2007). Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. Journal of Paediatrics and Child Health, 43(1–2), 19–24.PubMedCrossRefGoogle Scholar
  17. Hedges, L., & Olkin, I. (1985). Statistical methods for meta-analysis. New York, NY: Academic Press.Google Scholar
  18. Heudo-Medina, T., Sanchez-Meca, J., Marin-Marinez, F., & Botella, J. (2006). Assessing heterogeneity in meta-analysis: Q statistic or I2 index. Psychological Methods, 11, 193–206.CrossRefGoogle Scholar
  19. Holtmann, M., Bolte, S., & Poustka, F. (2007). Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: Association with autistic behavior domains and coexisting psychopathology. Psychopathology, 40(3), 172–177.PubMedCrossRefGoogle Scholar
  20. Jaselskis, C. A., Cook, E. H., Jr., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322–327.PubMedCrossRefGoogle Scholar
  21. Lecavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36(8), 1101–1114.PubMedCrossRefGoogle Scholar
  22. Lee, D. O., & Ousley, O. Y. (2006). Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. Journal of Child & Adolescent Psychopharmacology, 16(6), 737–746.CrossRefGoogle Scholar
  23. Leyfer, O. T., Folstein, S. E., Bacalman, S., Davis, N. O., Dinh, E., Morgan, J., et al. (2006). Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. Journal of Autism and Developmental Disorders, 36(7), 849–861.PubMedCrossRefGoogle Scholar
  24. Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121(3), e441–e448.PubMedCrossRefGoogle Scholar
  25. McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(5), e1312–e1321.PubMedCrossRefGoogle Scholar
  26. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 6(7), e1000097.PubMedCrossRefGoogle Scholar
  27. MTA Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archieves of General Psychiatry, 56(12), 1073–1086.CrossRefGoogle Scholar
  28. Oswald, D. P., & Sonenklar, N. A. (2007). Medication use among children with autism spectrum disorders. Journal of Child & Adolescent Psychopharmacology, 17(3), 348–355.CrossRefGoogle Scholar
  29. Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., et al. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism & Developmental Disords, 25(3), 283–294.CrossRefGoogle Scholar
  30. Research Units on Peadiatric Psychopharmolcology. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archieves of General Psychiatry, 62(11), 1266–1275.CrossRefGoogle Scholar
  31. Rosenberg, R., Mandell, D. S., Farmer, J. E., Law, J. K., Marvin, A. R., & Law, P. A. (2010). Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007–2008. Journal of Autism and Developmental Disorders, 40, 342–351.PubMedCrossRefGoogle Scholar
  32. Schachter, H., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ, 2001(165), 11.Google Scholar
  33. Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008). Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry, 47(8), 921–929.PubMedCrossRefGoogle Scholar
  34. Sinzig, J., Walter, D., & Doepfner, M. (2009). Attention deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder: Symptom or syndrome? Journal of Attention Disorder, 13(2), 117–126.CrossRefGoogle Scholar
  35. Spencer, T., Biederman, J., Wilens, T., Harding, M., O’Donnell, D., & Griffin, S. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry, 35(4), 409–432.PubMedCrossRefGoogle Scholar
  36. Sterne, J. A. C., Egger, M., & Moher, D. (2008). Addressing reporting biases. In J. P. T. Higgins & S. Green (Eds.), Cochrane handbook for systematic reviews of interventions (pp. 297–333). Chichester, UK: Wiley.Google Scholar
  37. Stigler, K. A., Desmond, L. A., Posey, D. J., Wiegand, R. E., & McDougle, C. J. (2004). A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. Journal of Child & Adolescent Psychopharmacology, 14(1), 49–56.CrossRefGoogle Scholar
  38. Swanson, J., Nolan, W, & Pelham, W. E. (1992). The SNAP-IV rating scale. Irvine, CA: University of California at Irvine.Google Scholar
  39. van der Meer, J. M. J., Oerlemans, A. M., van Stijn, D. J., Lappenschaar, M. G. A., de Sonneville, L. M. J., Buitelaar, J. K., et al. (2012). Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample. Journal of the American Academy of Child and Adolescent Psychiatry, 51(11), 1160–1172.PubMedCrossRefGoogle Scholar
  40. Wilson, D. (2005). Meta-analysis macros for SPSS.Google Scholar
  41. Yerys, B. D., Wallace, G. L., Sokoloff, J. L., Shook, D. A., James, J. D., & Kenworthy, L. (2009). Attention deficit/hyperactivity disorder symptoms moderate cognition and behavior in children with autism spectrum disorders. Autism Research, 2(6), 322–333.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Brian Reichow
    • 1
  • Fred R. Volkmar
    • 1
  • Michael H. Bloch
    • 1
  1. 1.Yale School of Medicine Child Study CenterNew HavenUSA

Personalised recommendations